|
English
|
正體中文
|
简体中文
|
总笔数 :2822924
|
|
造访人次 :
29977304
在线人数 :
429
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"haddad v"的相关文件
显示项目 1-4 / 4 (共1页)
1
每页显示[10|25|50]项目
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
|
Fukuoka M.;Rukazenkov Y;Haddad V;Young H;Mok T.S.K;Yang J.-J;Ichinose Y;Ohe Y;Sunpaweravong P;Chewaskulyong B;Margono B;Han B;Chih-Hsin Yang;Thongprasert S;Saijo N;Wu Y.-L; Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:26:35Z |
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
|
Heymach J.V.;Sood A.K;Hung M.-C;Wistuba I;Hong W.K;Lee J.J;Herbst R;Kim E.S;Wang J;Chih-Hsin Yang;Sequist L.V;Pena G.A;Tran H;Gomez D;Haddad V;Howells K;Lim S.-O;Poteete A;Fan Y;Li L;Liu D;Tong P;Diao L;Sun H;Nilsson M.B; Nilsson M.B; Sun H; Diao L; Tong P; Liu D; Li L; Fan Y; Poteete A; Lim S.-O; Howells K; Haddad V; Gomez D; Tran H; Pena G.A; Sequist L.V; CHIH-HSIN YANG; Wang J; Kim E.S; Herbst R; Lee J.J; Hong W.K; Wistuba I; Hung M.-C; Sood A.K; Heymach J.V. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
| 國立臺灣大學 |
2015 |
Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
|
Mok, T.; Saijo, N.; Thongprasert, S.; Yang, J. C. -H.; Wu, Y. -L.; Young, H.; Haddad, V.; Jiang, H.; Fukuoka, M.; 楊志新 |
显示项目 1-4 / 4 (共1页)
1
每页显示[10|25|50]项目
|
